QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
NASDAQ:CTSO

Cytosorbents News Headlines

$5.97
+0.12 (+2.05 %)
(As of 10/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.80
$6.11
50-Day Range
$5.85
$9.71
52-Week Range
$5.79
$11.68
Volume279,690 shs
Average Volume292,541 shs
Market Capitalization$258.91 million
P/E RatioN/A
Dividend YieldN/A
Beta0.3

Media Mentions By Week

Cytosorbents Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CTSO
News Sentiment

0.23

0.36

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CTSO Articles
This Week

14

2

CTSO Articles
Average Week

Get Cytosorbents News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.

Cytosorbents (NASDAQ CTSO) News Headlines Today

SourceHeadline
MarketBeat logoCytosorbents Co. (NASDAQ:CTSO) to Post Q3 2021 Earnings of ($0.16) Per Share, B. Riley Forecasts
americanbankingnews.com - October 18 at 1:26 AM
MarketBeat logoInvo Bioscience (OTCMKTS:IVOB) vs. Cytosorbents (NASDAQ:CTSO) Head-To-Head Contrast
americanbankingnews.com - October 16 at 11:20 AM
seekingalpha.com logoCytoSorbents gets enrollment underway in DrugSorb-ATR STAR–T trial - Seeking Alpha
seekingalpha.com - October 14 at 1:37 PM
MarketBeat logoCytosorbents (NASDAQ:CTSO) Earns Buy Rating from Analysts at B. Riley
americanbankingnews.com - October 14 at 8:52 AM
benzinga.com logoCytoSorbents Announces First Patient Enrolled In U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR Antithrombotic Removal System To Remove Ticagrelor During Cardiothoracic Surgery - Benzinga
benzinga.com - October 14 at 8:36 AM
finance.yahoo.com logoFirst Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery
finance.yahoo.com - October 14 at 8:36 AM
finance.yahoo.com logoCytosorbents (NASDAQ:CTSO shareholders incur further losses as stock declines 23% this week, taking three-year losses to 44%
finance.yahoo.com - October 14 at 8:36 AM
MarketBeat logoCytosorbents (NASDAQ:CTSO) Price Target Cut to $10.00
americanbankingnews.com - October 13 at 12:04 PM
MarketBeat logo$11.96 Million in Sales Expected for Cytosorbents Co. (NASDAQ:CTSO) This Quarter
americanbankingnews.com - October 12 at 2:02 AM
MarketBeat logoCytosorbents Co. (NASDAQ:CTSO) Expected to Post Earnings of -$0.10 Per Share
americanbankingnews.com - October 10 at 9:16 PM
nasdaq.com logoWhat Kind Of Investors Own Most Of Cytosorbents Corporation (NASDAQ:CTSO)? - Nasdaq
nasdaq.com - October 10 at 1:34 PM
MarketBeat logoCytosorbents (NASDAQ:CTSO) Rating Reiterated by SVB Leerink
americanbankingnews.com - October 10 at 9:48 AM
seekingalpha.com logoCytosorbents: Endocarditis Trial Failed To Remove Risk In Heart Surgery Patients - Seeking Alpha
seekingalpha.com - October 8 at 8:53 AM
streetinsider.com logoCytosorbents (CTSO) Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference - StreetInsider.com
streetinsider.com - October 7 at 7:20 PM
finance.yahoo.com logoCTSO Oct 2021 12.500 call
finance.yahoo.com - September 29 at 2:16 AM
fortune.com logoHealth insurers justify passing COVID treatment costs on to patients despite massive profits - Fortune
fortune.com - September 24 at 6:21 PM
finance.yahoo.com logoCytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients with COVID-19
finance.yahoo.com - September 14 at 1:36 PM
finance.yahoo.com logoCytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery - Yahoo Finance
finance.yahoo.com - September 10 at 8:47 PM
seekingalpha.com logoCytoSorbents files IDE for U.S. trial on apixaban/rivaroxaban removal during cardiothoracic surgery - Seeking Alpha
seekingalpha.com - September 10 at 3:47 PM
finance.yahoo.com logoCytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO) - Yahoo Finance
finance.yahoo.com - September 10 at 1:44 AM
finance.yahoo.com logoCytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
finance.yahoo.com - September 8 at 7:42 PM
finance.yahoo.com logoA Look At The Intrinsic Value Of Cytosorbents Corporation (NASDAQ:CTSO)
finance.yahoo.com - September 8 at 2:41 PM
nasdaq.com logoCytosorbents (NASDAQ:CTSO) shareholders have earned a 12% CAGR over the last five years - Nasdaq
nasdaq.com - September 6 at 7:35 AM
streetinsider.com logoForm 8-K Cytosorbents Corp For: Aug 30 - StreetInsider.com
streetinsider.com - September 2 at 2:44 AM
nasdaq.com logoIntuit Reportedly In Talks To Buy Mailchimp For Around $10 Bln - Nasdaq
nasdaq.com - September 1 at 4:41 PM
nasdaq.com logoSeelos Therapeutics Promotes Michael Golembiewski To CFO - Quick Facts - Nasdaq
nasdaq.com - September 1 at 4:41 PM
nasdaq.com logoU.S. CTC Registry Shows High Survival Using CytoSorb In Critically Ill COVID-19 Patients On ECMO - Nasdaq
nasdaq.com - September 1 at 4:41 PM
finance.yahoo.com logoCytoSorbents' Product Associated With High Survival In Critically Ill COVID-19 Patients
finance.yahoo.com - September 1 at 4:41 PM
finance.yahoo.com logoTopline Results from CytoSorbents' U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
finance.yahoo.com - September 1 at 8:50 AM
finance.yahoo.com logoItaly reports 53 coronavirus deaths on Monday, 4,257 new cases - Yahoo Finance
finance.yahoo.com - August 30 at 10:07 PM
finance.yahoo.com logoCytoSorbents, Aferetica Launch Organ Perfusion System In Italy
finance.yahoo.com - August 30 at 5:06 PM
streetinsider.com logoCytosorbents (CTSO), Aferetica Launch PerSorb Adsorber and PerLife Organ Perfusion System in Italy - StreetInsider.com
streetinsider.com - August 30 at 8:34 AM
benzinga.com logoLooking into CytoSorbents's Return on Capital Employed - Benzinga
benzinga.com - August 20 at 4:55 PM
finance.yahoo.com logoSecond U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR™ Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery
finance.yahoo.com - August 12 at 4:33 PM
finance.yahoo.com logoCytoSorbents Q2 Earnings Lag Consensus, Higher Costs Weigh On Bottom Line - Yahoo Finance
finance.yahoo.com - August 4 at 2:47 PM
finance.yahoo.com logoCytoSorbents Q2 Earnings Lag Consensus, Higher Costs Weigh On Bottom Line
finance.yahoo.com - August 4 at 2:46 PM
benzinga.com logoCytoSorbents Q2 Earnings Lag Consensus, Higher Costs Weigh On Bottom Line - Benzinga
benzinga.com - August 4 at 9:46 AM
finance.yahoo.com logoCytoSorbents Reports Second Quarter 2021 Financial and Operational Results
finance.yahoo.com - August 3 at 6:41 PM
finance.yahoo.com logoCould The Cytosorbents Corporation (NASDAQ:CTSO) Ownership Structure Tell Us Something Useful? - Yahoo Finance
finance.yahoo.com - August 3 at 1:41 PM
markets.businessinsider.com logoThe Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business - Markets Insider
markets.businessinsider.com - August 3 at 8:41 AM
finance.yahoo.com logoCould The Cytosorbents Corporation (NASDAQ:CTSO) Ownership Structure Tell Us Something Useful?
finance.yahoo.com - August 3 at 8:41 AM
benzinga.com logoCytoSorbents Sponsored Study Titled 'Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) (STAR-T)' Posted To ClinicalTrials.Gov; Study Not Yet Recruiting - Benzinga
benzinga.com - July 26 at 5:31 PM
nasdaq.com logoCytosorbents Corporation Common Stock (CTSO)
nasdaq.com - July 25 at 7:44 PM
finance.yahoo.com logoInsights Extracorporeal Membrane Oxygenation Machine Global Market to 2025 - Miniaturization of ECMO Machines Presents Opportunities - ResearchAndMarkets.com - Yahoo Finance Australia
finance.yahoo.com - July 23 at 9:48 AM
finance.yahoo.com logoCytoSorbents to Report Second Quarter 2021 Operating and Financial Results - Yahoo Finance
finance.yahoo.com - July 19 at 10:13 AM
finance.yahoo.com logoCytoSorbents to Report Second Quarter 2021 Operating and Financial Results
finance.yahoo.com - July 19 at 10:13 AM
streetinsider.com logoForm S-3 Cytosorbents Corp - StreetInsider.com
streetinsider.com - July 15 at 2:20 PM
finance.yahoo.com logoDrinkworks by Keurig's ready to dispense cocktails continue growth amid reopening - Yahoo Finance
finance.yahoo.com - July 7 at 6:06 PM
finance.yahoo.com logoNew Zealand health regulator approves use of Janssen COVID-19 vaccine - Yahoo Finance
finance.yahoo.com - July 7 at 8:05 AM
streetinsider.com logoCytosorbents (CTSO) Receives Full FDA Approval of IDE for US STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery - StreetInsider.com
streetinsider.com - July 7 at 8:05 AM
Get Cytosorbents News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.